| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yusuke Nakata, Nobuhisa Kanahara, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iy. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. International clinical psychopharmacology. vol 32. issue 3. 2017-12-18. PMID:28067751. |
although the effectiveness of clozapine (clz) for patients with treatment-resistant schizophrenia (trs) has been well established, its active mechanism has not been completely clarified. |
2017-12-18 |
2023-08-13 |
Not clear |
| Lauren I Kasoff, Kwangmi Ahn, Peter Gochman, Diane D Broadnax, Judith L Rapopor. Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia. Journal of child and adolescent psychopharmacology. vol 26. issue 5. 2017-12-14. PMID:26784704. |
strong treatment response and high maintenance rates of clozapine in childhood-onset schizophrenia. |
2017-12-14 |
2023-08-13 |
Not clear |
| Amir Krivoy, Irit Gil-Ad, Igor Tarasenko, Abraham Weizman, Michal Tale. Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia:A preliminary study. Behavioural brain research. vol 323. 2017-12-13. PMID:28167336. |
schizophrenia patients who do not respond to clozapine treatment represent the most debilitating type of schizophrenia with unmet needs for novel interventions. |
2017-12-13 |
2023-08-13 |
mouse |
| Taylor M Mehta, Ryan J Van Lieshou. A review of the safety of clozapine during pregnancy and lactation. Archives of women's mental health. vol 20. issue 1. 2017-12-11. PMID:27704220. |
clozapine is an antipsychotic used in the management of treatment-resistant schizophrenia. |
2017-12-11 |
2023-08-13 |
Not clear |
| Taylor M Mehta, Ryan J Van Lieshou. A review of the safety of clozapine during pregnancy and lactation. Archives of women's mental health. vol 20. issue 1. 2017-12-11. PMID:27704220. |
while the available literature on clozapine use during the perinatal period is very limited, the risks of clozapine use during pregnancy and the postpartum period should be discussed with women and weighed against those associated with other treatments and partially or untreated schizophrenia. |
2017-12-11 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, J D Smith, L de Haa. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychological medicine. vol 46. issue 9. 2017-11-28. PMID:27048954. |
clozapine augmentation with memantine targets altered nmda receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. |
2017-11-28 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, J D Smith, L de Haa. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychological medicine. vol 46. issue 9. 2017-11-28. PMID:27048954. |
we evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia. |
2017-11-28 |
2023-08-13 |
Not clear |
| Amir Krivoy, Fiona Gaughran, Abraham Weizman, Gerome Breen, James H MacCab. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. International clinical psychopharmacology. vol 31. issue 4. 2017-11-27. PMID:25563806. |
clozapine is currently the ultimate effective therapy for otherwise treatment-refractory schizophrenia. |
2017-11-27 |
2023-08-13 |
Not clear |
| Ryan S Sultan, Mark Olfson, Christoph U Correll, Erica J Dunca. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. The Journal of clinical psychiatry. vol 78. issue 8. 2017-11-20. PMID:28742291. |
concerns exist that clozapine is underutilized in the management of treatment-resistant schizophrenia. |
2017-11-20 |
2023-08-13 |
Not clear |
| Alper Bas, Gozde Gultekin, Said Incir, Tuba Ocek Bas, Murat Emul, Alaatin Dura. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. Psychiatry research. vol 247. 2017-11-17. PMID:27871032. |
level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. |
2017-11-17 |
2023-08-13 |
Not clear |
| Alper Bas, Gozde Gultekin, Said Incir, Tuba Ocek Bas, Murat Emul, Alaatin Dura. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. Psychiatry research. vol 247. 2017-11-17. PMID:27871032. |
the aim of this study is investigating the relationship between serum thioredoxin levels and cognitive functions in acute psychotic episode and remission state patients with schizophrenia; and examining whether there were differences between patients using clozapine and other atypical antipsychotics; including risperidone, olanzapine and amisulpride. |
2017-11-17 |
2023-08-13 |
Not clear |
| J Lally, O Ajnakina, M Di Forti, A Trotta, A Demjaha, A Kolliakou, V Mondelli, T Reis Marques, C Pariante, P Dazzan, S S Shergil, O D Howes, A S David, J H MacCabe, F Gaughran, R M Murra. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological medicine. vol 46. issue 15. 2017-11-16. PMID:27605254. |
clozapine remains the only evidence-based antipsychotic for treatment-resistant schizophrenia (trs). |
2017-11-16 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Yuji Yada, Ryuhei So, Manabu Takaki, Norihito Yamad. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. Psychiatry research. vol 250. 2017-11-16. PMID:28142068. |
the critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. |
2017-11-16 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Yuji Yada, Ryuhei So, Manabu Takaki, Norihito Yamad. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. Psychiatry research. vol 250. 2017-11-16. PMID:28142068. |
previous studies have suggested that a delay in initiating clozapine is one of the predictors of outcomes in treatment-resistant schizophrenia (trs). |
2017-11-16 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Yuji Yada, Ryuhei So, Manabu Takaki, Norihito Yamad. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. Psychiatry research. vol 250. 2017-11-16. PMID:28142068. |
clinicians should reduce the delay in initiating clozapine to less than 3 years to improve symptomatic outcomes in trs and to prevent clozapine-resistant schizophrenia. |
2017-11-16 |
2023-08-13 |
Not clear |
| Jonathan G Leung, M Earth Hasassri, Jason N Barreto, Sarah Nelson, Robert J Morga. Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine. Psychosomatics. vol 58. issue 2. 2017-11-09. PMID:28153339. |
clozapine is the antipsychotic of choice for treatment-resistant schizophrenia; however, rigorous monitoring is required to prevent or detect adverse drug events that contribute to morbidity and mortality. |
2017-11-09 |
2023-08-13 |
Not clear |
| Theresa Wimberley, Henrik Støvring, Holger J Sørensen, Henriette T Horsdal, James H MacCabe, Christiane Gass. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. The lancet. Psychiatry. vol 3. issue 4. 2017-11-02. PMID:26922475. |
identification of patients at high risk of treatment-resistant schizophrenia at the time of schizophrenia diagnosis would be of great clinical benefit in minimising the delay to clozapine treatment in patients unlikely to respond to non-clozapine antipsychotics. |
2017-11-02 |
2023-08-13 |
Not clear |
| Yumiko Akamine, Yuka Sugawara-Kikuchi, Tsukasa Uno, Tetsuo Shimizu, Masatomo Miur. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Annals of clinical biochemistry. vol 54. issue 6. 2017-10-30. PMID:27932669. |
quantification of the steady-state plasma concentrations of clozapine and n-desmethylclozapine in japanese patients with schizophrenia using a novel hplc method and the effects of cyps and abc transporters polymorphisms. |
2017-10-30 |
2023-08-13 |
human |
| Lulu Jiang, Xuefei Wu, Shuo Wang, Shih-Heng Chen, Hui Zhou, Belinda Wilson, Chun-Yang Jin, Ru-Band Lu, Keqin Xie, Qingshan Wang, Jau-Shyong Hon. Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. Journal of neuroinflammation. vol 13. issue 1. 2017-10-10. PMID:27184631. |
clozapine, an atypical antipsychotic medication, has been effectively used to treat refractory schizophrenia. |
2017-10-10 |
2023-08-13 |
Not clear |
| Theresa Wimberley, James H MacCabe, Thomas M Laursen, Holger J Sørensen, Aske Astrup, Henriette T Horsdal, Christiane Gasse, Henrik Støvrin. Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. The American journal of psychiatry. vol 174. issue 10. 2017-10-10. PMID:28750580. |
mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. |
2017-10-10 |
2023-08-13 |
Not clear |